Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
According to Akili, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 22.70. At the end of 2022 the company had a P/S ratio of 103.60.
Year | P/S ratio |
---|---|
2023 | 22.70 |
2022 | 103.60 |
2021 | 588.60 |
2020 | 199.84 |
2019 | 39.39 |